The third meeting of NanoGSkin project took place in Bratislava, Slovakia, during the Euronanomed Review Seminar for Funded Projects.
The partners gathered together in order to discuss the outcomes derived from the first year of the project and to plan the forthcoming tasks of the WP3 and WP5.
Efforts made during the first year have led to very interesting data about combining the bioartificial skin substitute with nanoparticles. The most relevant outcomes showed that EGFP-NPs enhance keratinocyte expansion and proved that antibiotic-NPs have a clear dose-dependent inhibition effect on Pseudomonas aeruginosa growth. These results firmly encourage the NanoGSkin partners to continue with the research. In the short term, the partners agreed on studying the NPs long-term stability and the release of antibiotic from the NPs, as well as on selecting which NPs will be used in the upcoming in vivo trials.
Related to this last aspect, the NanoGSkin Consortium is fully aware of the Ethics of this research involving animals. INERIS, the French National Institute for Industrial Environment and Risks, will collaborate with the NanoGSkin Consortium by providing their infrastructure and facilities for some toxicity trials. With this aim, INERIS participated in the 2019 NanoGSkin meeting to introduce their future role in the NanoGSkin project and the requirements that should be taken into account to perform this kind of experiments.
In conclusion, the meeting was very productive for the project since all the partners and collaborators took time to thoroughly revise the project and planed how to move forward in the next months.